Symbols / EFTR
EFTR Chart
About
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 940.00 |
| Enterprise Value | -5.13M | Income | -34.63M | Sales | — |
| Book/sh | 0.21 | Cash/sh | 5.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | 0.00 | P/C | — |
| EV/EBITDA | 0.16 | EV/Sales | — | Quick Ratio | 0.99 |
| Current Ratio | 1.03 | Debt/Eq | 2448.37 | LT Debt/Eq | — |
| EPS (ttm) | -12.57 | EPS next Y | -2.25 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-05-09 16:00 | ROA | -83.33% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.70M |
| Shs Float | 4.67M | Short Float | 1.97% | Short Ratio | 0.97 |
| Short Interest | — | 52W High | 0.01 | 52W Low | 0.00 |
| Beta | 0.98 | Avg Volume | 2.68K | Volume | 331.00 |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-67.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2024-02-06 | main | HC Wainwright & Co. | Buy → Buy | $24 |
- eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq - Stock Titan Mon, 24 Jun 2024 07
- 3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year - Nasdaq hu, 11 May 2023 07
- Why Is SunCar Technology (SDA) Stock Down 27% Today? - InvestorPlace Fri, 26 May 2023 07
- Credit Suisse Maintains eFFECTOR Therapeutics (EFTR) Outperform Recommendation - Nasdaq Wed, 10 May 2023 07
- Indian Motorcycle and Super73 release a fast e-bike that won’t need a motorcycle license - Electrek Sat, 05 Mar 2022 08
- Why Is Marvell Technology (MRVL) Stock Up 17% Today? - InvestorPlace Fri, 26 May 2023 07
- eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails - Yahoo Finance Fri, 05 Apr 2024 07
- LWAC Stock: eFFECTOR Therapeutics SPAC Merger News Sends Shares Skyrocketing - Nasdaq Wed, 25 Aug 2021 07
- Head-To-Head Comparison: eFFECTOR Therapeutics (NASDAQ:EFTR) & Bio-Path (NASDAQ:BPTH) - Defense World Mon, 16 Feb 2026 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1387 | 2334 | — | Stock Award(Grant) at price 1.68 per share. | BYRNES MICHAEL | Chief Financial Officer | — | 2024-05-15 00:00:00 | D |
| 1 | 1806 | 3039 | — | Stock Award(Grant) at price 1.68 per share. | WORLAND STEPHEN T | Chief Executive Officer | — | 2024-05-15 00:00:00 | D |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 13.07M |
| TaxRateForCalcs | 0.00 | 0.00 | 0.27 |
| NormalizedEBITDA | -32.79M | -32.48M | -30.83M |
| TotalUnusualItems | 6.00K | 12.12M | 48.42M |
| TotalUnusualItemsExcludingGoodwill | 6.00K | 12.12M | 48.42M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -35.81M | -22.66M | 15.80M |
| ReconciledDepreciation | 111.00K | 53.00K | 24.00K |
| EBITDA | -32.78M | -20.36M | 17.59M |
| EBIT | -32.89M | -20.41M | 17.56M |
| NetInterestIncome | -1.95M | -1.81M | -1.76M |
| InterestExpense | 2.92M | 2.25M | 1.76M |
| InterestIncome | 972.00K | 439.00K | 6.00K |
| NormalizedIncome | -35.82M | -34.79M | -19.55M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -35.81M | -22.66M | 15.80M |
| TotalExpenses | 33.84M | 32.40M | 31.90M |
| TotalOperatingIncomeAsReported | -33.84M | -32.40M | -31.90M |
| DilutedAverageShares | 2.19M | 1.65M | 1.44M |
| BasicAverageShares | 2.19M | 1.65M | 604.23K |
| DilutedEPS | -16.37 | -13.75 | 11.00 |
| BasicEPS | -16.37 | -13.75 | 26.25 |
| DilutedNIAvailtoComStockholders | -35.81M | -22.66M | 15.80M |
| AverageDilutionEarnings | 0.00 | ||
| NetIncomeCommonStockholders | -35.81M | -22.66M | 15.80M |
| OtherunderPreferredStockDividend | 0.00 | ||
| NetIncome | -35.81M | -22.66M | 15.80M |
| NetIncomeIncludingNoncontrollingInterests | -35.81M | -22.66M | 15.80M |
| NetIncomeContinuousOperations | -35.81M | -22.66M | 15.80M |
| TaxProvision | 0.00 | ||
| PretaxIncome | -35.81M | -22.66M | 15.80M |
| OtherIncomeExpense | -20.00K | 11.55M | 49.45M |
| OtherNonOperatingIncomeExpenses | -26.00K | -574.00K | 1.03M |
| SpecialIncomeCharges | 6.00K | 12.12M | 48.42M |
| OtherSpecialCharges | 492.00K | ||
| RestructuringAndMergernAcquisition | -6.00K | -12.12M | -48.91M |
| NetNonOperatingInterestIncomeExpense | -1.95M | -1.81M | -1.76M |
| InterestExpenseNonOperating | 2.92M | 2.25M | 1.76M |
| InterestIncomeNonOperating | 972.00K | 439.00K | 6.00K |
| OperatingIncome | -33.84M | -32.40M | -31.90M |
| OperatingExpense | 33.84M | 32.40M | 31.90M |
| OtherOperatingExpenses | -3.55M | -1.43M | |
| ResearchAndDevelopment | 22.92M | 23.31M | 19.96M |
| SellingGeneralAndAdministration | 10.93M | 12.64M | 13.37M |
| GeneralAndAdministrativeExpense | 10.93M | 12.64M | 13.37M |
| OtherGandA | 10.93M | 12.64M | 13.37M |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | 2021-12-31 | |
|---|---|---|---|
| TreasurySharesNumber | 12.00K | 300.00K | |
| OrdinarySharesNumber | 2.98M | 1.67M | 1.62M |
| ShareIssued | 2.98M | 1.67M | 1.62M |
| NetDebt | 5.61M | 11.45M | |
| TotalDebt | 20.55M | 20.28M | 20.03M |
| TangibleBookValue | -5.79M | 3.90M | 17.28M |
| InvestedCapital | 14.69M | 24.06M | 37.14M |
| WorkingCapital | -5.96M | 2.94M | 48.92M |
| NetTangibleAssets | -5.79M | 3.90M | 17.28M |
| CapitalLeaseObligations | 60.00K | 120.00K | 170.00K |
| CommonStockEquity | -5.79M | 3.90M | 17.28M |
| TotalCapitalization | -5.79M | 3.90M | 37.14M |
| TotalEquityGrossMinorityInterest | -5.79M | 3.90M | 17.28M |
| StockholdersEquity | -5.79M | 3.90M | 17.28M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -18.00K | 0.00 |
| OtherEquityAdjustments | -18.00K | ||
| RetainedEarnings | -179.38M | -143.57M | -120.90M |
| AdditionalPaidInCapital | 173.58M | 147.48M | 138.18M |
| CapitalStock | 0.00 | 0.00 | 4.00K |
| CommonStock | 0.00 | 0.00 | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 26.34M | 25.18M | 36.77M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 543.00K | 106.00K | 32.79M |
| OtherNonCurrentLiabilities | 6.00K | 12.13M | |
| PreferredSecuritiesOutsideStockEquity | 0.00 | ||
| DerivativeProductLiabilities | 40.00K | 40.00K | 678.00K |
| NonCurrentAccruedExpenses | 503.00K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 60.00K | 19.99M |
| LongTermCapitalLeaseObligation | 0.00 | 60.00K | 126.00K |
| LongTermDebt | 19.86M | ||
| CurrentLiabilities | 25.80M | 25.07M | 3.98M |
| CurrentDebtAndCapitalLeaseObligation | 20.55M | 20.22M | 44.00K |
| CurrentCapitalLeaseObligation | 60.00K | 60.00K | 44.00K |
| CurrentDebt | 20.48M | 20.16M | |
| OtherCurrentBorrowings | 20.16M | ||
| LineOfCredit | 20.48M | 20.16M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.59M | 1.39M | 1.34M |
| PayablesAndAccruedExpenses | 3.66M | 3.47M | 2.59M |
| CurrentAccruedExpenses | 1.33M | 1.98M | 1.72M |
| InterestPayable | 223.00K | 197.00K | 133.00K |
| Payables | 2.33M | 1.49M | 867.00K |
| TotalTaxPayable | 463.00K | 351.00K | |
| IncomeTaxPayable | 463.00K | 351.00K | |
| AccountsPayable | 2.33M | 1.49M | 516.00K |
| TotalAssets | 20.54M | 29.08M | 54.06M |
| TotalNonCurrentAssets | 706.00K | 1.06M | 1.16M |
| OtherNonCurrentAssets | 513.00K | 711.00K | 903.00K |
| NetPPE | 193.00K | 352.00K | 257.00K |
| AccumulatedDepreciation | -324.00K | -216.00K | -204.00K |
| GrossPPE | 517.00K | 568.00K | 461.00K |
| Leases | 188.00K | 188.00K | 0.00 |
| ConstructionInProgress | 14.00K | 29.00K | 74.00K |
| OtherProperties | 83.00K | 141.00K | 196.00K |
| MachineryFurnitureEquipment | 232.00K | 210.00K | 191.00K |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 19.84M | 28.01M | 52.90M |
| OtherCurrentAssets | 1.47M | 1.70M | 3.19M |
| PrepaidAssets | 3.19M | ||
| CashCashEquivalentsAndShortTermInvestments | 18.37M | 26.31M | 49.70M |
| OtherShortTermInvestments | 3.50M | 17.60M | 0.00 |
| CashAndCashEquivalents | 14.88M | 8.71M | 49.70M |
| CashEquivalents | 8.71M | 49.70M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -29.65M | -26.09M | -24.93M |
| RepaymentOfDebt | 0.00 | -13.94M | |
| IssuanceOfDebt | 0.00 | 19.84M | |
| IssuanceOfCapitalStock | 21.18M | 2.80M | 0.00 |
| CapitalExpenditure | -97.00K | -192.00K | -42.00K |
| InterestPaidSupplementalData | 2.53M | 1.82M | 1.34M |
| EndCashPosition | 14.88M | 8.71M | 49.70M |
| BeginningCashPosition | 8.71M | 49.70M | 15.22M |
| ChangesInCash | 6.17M | -40.99M | 34.49M |
| FinancingCashFlow | 21.23M | 2.77M | 58.81M |
| CashFlowFromContinuingFinancingActivities | 21.23M | 2.77M | 58.81M |
| NetOtherFinancingCharges | -37.00K | 52.86M | |
| ProceedsFromStockOptionExercised | 56.00K | 3.00K | 56.00K |
| NetCommonStockIssuance | 21.18M | 2.80M | 0.00 |
| CommonStockIssuance | 21.18M | 2.80M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 5.89M | |
| NetLongTermDebtIssuance | 0.00 | 5.89M | |
| LongTermDebtPayments | 0.00 | -13.94M | |
| LongTermDebtIssuance | 0.00 | 19.84M | |
| InvestingCashFlow | 14.48M | -17.86M | 565.00K |
| CashFlowFromContinuingInvestingActivities | 14.48M | -17.86M | 565.00K |
| NetInvestmentPurchaseAndSale | 14.58M | -17.67M | 0.00 |
| SaleOfInvestment | 31.75M | 34.75M | 0.00 |
| PurchaseOfInvestment | -17.17M | -52.42M | 0.00 |
| NetPPEPurchaseAndSale | -97.00K | -192.00K | 565.00K |
| SaleOfPPE | 0.00 | 607.00K | |
| PurchaseOfPPE | -97.00K | -192.00K | -42.00K |
| OperatingCashFlow | -29.55M | -25.90M | -24.89M |
| CashFlowFromContinuingOperatingActivities | -29.55M | -25.90M | -24.89M |
| ChangeInWorkingCapital | 1.69M | 2.68M | -238.00K |
| ChangeInOtherWorkingCapital | -1.00K | 4.00K | -11.00K |
| ChangeInOtherCurrentAssets | 192.00K | 192.00K | -903.00K |
| ChangeInPayablesAndAccruedExpense | 907.00K | 906.00K | 1.95M |
| ChangeInAccruedExpense | 52.00K | -52.00K | 1.79M |
| ChangeInPayable | 855.00K | 958.00K | 155.00K |
| ChangeInAccountPayable | 855.00K | 958.00K | 155.00K |
| ChangeInPrepaidAssets | 587.00K | 1.57M | -1.27M |
| OtherNonCashItems | 346.00K | -10.62M | -48.59M |
| StockBasedCompensation | 4.59M | 5.33M | 8.66M |
| AmortizationOfSecurities | -473.00K | -37.00K | 0.00 |
| DepreciationAmortizationDepletion | 111.00K | 53.00K | 24.00K |
| DepreciationAndAmortization | 111.00K | 53.00K | 24.00K |
| Depreciation | 111.00K | 53.00K | |
| OperatingGainsLosses | -3.00K | -637.00K | -539.00K |
| GainLossOnInvestmentSecurities | -638.00K | -1.03M | |
| NetIncomeFromContinuingOperations | -35.81M | -22.66M | 15.80M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for EFTR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|